Table S2. Summary of genomic characteristics of GEPNEC patients undergone target NGS.
| Year | Author (ref.) | N (n)* | Primary site (N) | N | % | ||||||||||
| LCNEC ¶ | Panel | TP53 | RB1 | KRAS | BRAF | APC | CTNNB1 | CDKN2A | PI3KCA | ERBB2 | |||||
| GEPENC, gastroenteropancreatic neuroendocrine carcinoma; NGS, next-generation sequencing; MiNEN, mixed neuroendocrine-non-neuroendocrine neoplasia; LCNEC, large-cell NEC; WES, whole-exome sequencing. *, N means numbers of the total GEPNEC samples, n referred to the MiNEN mentioned in the cohort (if accessible) in the study; ¶, numbers of LCNEC patients; §, Puccini et al. and Busico et al. have not provided the relative proportions of NEC among the G3 NEN; ‖, Venizelos et al. have included 29 G3 NET into the total 181 patients. | |||||||||||||||
| References | |||||||||||||||
|
1. Karkouche R, Bachet JB, Sandrini J, et al. Colorectal neuroendocrine carcinomas and adenocarcinomas share oncogenic pathways. A clinico-pathologic study of 12 cases. Eur J Gastroenterol Hepatol 2012;24:1430-7. | |||||||||||||||
|
2. Scardoni M, Vittoria E, Volante M, et al. Mixed adenoneuroendocrine carcinomas of the gastrointestinal tract: Targeted next-generation sequencing suggests a monoclonal origin of the two components. Neuroendocrinology 2014;100:310-6. | |||||||||||||||
|
3. Sahnane N, Furlan D, Monti M, et al. Microsatellite unstable gastrointestinal neuroendocrine carcinomas: A new clinicopathologic entity. Endocr Relat Cancer 2015;22:35-45. | |||||||||||||||
|
4. Olevian DC, Nikiforova MN, Chiosea S, et al. Colorectal poorly differentiated neuroendocrine carcinomas frequently exhibit BRAF mutations and are associated with poor overall survival. Hum Pathol 2016;49:124-34. | |||||||||||||||
|
5. Bergsland EK, Roy R, Stephens P, et al. Genomic profiling to distinguish poorly differentiated neuroendocrine carcinomas arising in different sites. J Clin Oncol 2016;34(15_suppl):4020. | |||||||||||||||
|
6. Vijayvergia N, Boland PM, Handorf E, et al. Molecular profiling of neuroendocrine malignancies to identify prognostic and therapeutic markers: A Fox Chase Cancer Center Pilot Study. Br J Cancer 2016;115:564-70. | |||||||||||||||
|
7. Makuuchi R, Terashima M, Kusuhara M, et al. Comprehensive analysis of gene mutation and expression profiles in neuroendocrine carcinomas of the stomach. Biomed Res 2017;38:19-27. | |||||||||||||||
|
8. Woischke C, Schaaf CW, Yang HM, et al. In-depth mutational analyses of colorectal neuroendocrine carcinomas with adenoma or adenocarcinoma components. Mod Pathol 2017;30:95-103. | |||||||||||||||
|
9. Takizawa N, Ohishi Y, Hirahashi M, et al. Molecular characteristics of colorectal neuroendocrine carcinoma; Similarities with adenocarcinoma rather than neuroendocrine tumor. Hum Pathol 2015;46:1890-900. | |||||||||||||||
|
10. Jesinghaus M, Konukiewitz B, Keller G, et al. Colorectal mixed adenoneuroendocrine carcinomas and neuroendocrine carcinomas are genetically closely related to colorectal adenocarcinomas. Mod Pathol 2017;30:610-9. | |||||||||||||||
|
11. Konukiewitz B, Jesinghaus M, Steiger K, et al. Pancreatic neuroendocrine carcinomas reveal a closer relationship to ductal adenocarcinomas than to neuroendocrine tumors G3. Hum Pathol 2018;77:70-9. | |||||||||||||||
|
12. Shamir E, Devine WP, Jones K, et al. Genomic profiling of colorectal neuroendocrine carcinoma (NEC) reveals multiple mechanisms of RB1 inactivation. Lab Invest 2018;98(suppl 1):301. | |||||||||||||||
|
13. Chen L, Liu M, Zhang Y, et al. Genetic characteristics of colorectal neuroendocrine carcinoma: more similar to colorectal adenocarcinoma. Clin Colorectal Cancer 2021;20:177-85. | |||||||||||||||
|
14. Dizdar L, Werner TA, Drusenheimer JC, et al. BRAFV600E mutation: A promising target in colorectal neuroendocrine carcinoma. Int J Cancer 2019;144:1379-90. | |||||||||||||||
|
15. Krishnamurthy K, Cusnir M, Schwartz M, et al. Retinoblastoma co-repressor 1 (RB) and cyclin-dependent kinase inhibitor (CDKN) as a multi-gene panel for differentiating pulmonary from non-pulmonary origin in metastatic neuroendocrine carcinomas. Pathol Res Pract 2020;216:153051. | |||||||||||||||
|
16. Tanaka H, Hijioka S, Hosoda W, et al. Pancreatic neuroendocrine carcinoma G3 may be heterogeneous and could be classified into two distinct groups. Pancreatology 2020;20:1421-7. | |||||||||||||||
|
17. Busico A, Maisonneuve P, Prinzi N, et al. Gastroenteropancreatic high-grade neuroendocrine neoplasms: histology and molecular analysis, two sides of the same coin. Neuroendocrinology 2020;110:616-29. | |||||||||||||||
|
18. Puccini A, Poorman K, Salem ME, et al. Comprehensive genomic profiling of gastroenteropancreatic neuroendocrine neoplasms (GEP-NENs). Clin Cancer Res 2020;26:5943-51. | |||||||||||||||
|
19. Koh J, Nam SK, Kwak Y, et al. Comprehensive genetic features of gastric mixed adenoneuroendocrine carcinomas and pure neuroendocrine carcinomas. J Pathol 2021;253:94-105. | |||||||||||||||
|
20. Ishida S, Akita M, Fujikura K, et al. Neuroendocrine carcinoma and mixed neuroendocrine-non-neuroendocrine neoplasm of the stomach: a clinicopathological and exome sequencing study. Hum Pathol 2021;110:1-10. | |||||||||||||||
|
21. Liu F, Li Y, Ying D, et al. Whole-exome mutational landscape of neuroendocrine carcinomas of the gallbladder. Signal Transduct Target Ther 2021;6:55. | |||||||||||||||
|
22. de Bitter TJJ, Kroeze LI, de Reuver PR, et al. Unraveling neuroendocrine gallbladder cancer: comprehensive clinicopathologic and molecular characterization. JCO Precis Oncol 2021;5:PO.20.00487. | |||||||||||||||
|
23. Venizelos A, Elvebakken H, Perren A, et al. The molecular characteristics of high-grade gastroenteropancreatic neuroendocrine neoplasms. Endocr Relat Cancer 2021;29:1-14. | |||||||||||||||
|
24. Lee SM, Sung CO. Comprehensive analysis of mutational and clinicopathologic characteristics of poorly differentiated colorectal neuroendocrine carcinomas. Sci Rep 2021;11:6203. | |||||||||||||||
|
25. Yachida S, Totoki Y, Noë M, et al. Comprehensive genomic profiling of neuroendocrine carcinomas of the gastrointestinal system. Cancer Discov 2022;12:692-711. | |||||||||||||||
|
26. Wu H, Yu Z, Liu Y, et al. Genomic characterization reveals distinct mutation landscapes and therapeutic implications in neuroendocrine carcinomas of the gastrointestinal tract. Cancer Commun (Lond) 2022;42:1367-86. | |||||||||||||||
| 2012 | Karkouche R ( 1) | 12 (8) | Colorectum | 12 | − | − | − | 33 | 17 | − | − | − | − | − | |
| 2017 | Scardoni M ( 2) | 6 (−) | Stomach | − | − | 83 | 17 | 17 | − | − | 0 | − | − | − | |
| 2015 | Sahnane N ( 3) | 89 (36) | Esophagus (6), stomach (36),
duodenum (4), colorectum (37), gallbladder (3), pancreas (3) |
40 | − | − | − | 17 | 7 | − | − | − | − | − | |
| 2016 | Olevian DC. ( 4) | 29 (−) | Colorectum | − | − | − | − | 17 | 59 | − | − | − | − | − | |
| 2016 | Bergsland EK ( 5) | 123 | Pancreas | − | 192 | 18 | 10 | 7 | − | 3 | − | 21 | − | − | |
| 2016 | Bergsland EK ( 5) | 92 | Colon | − | 192 | 59 | 34 | 37 | − | 47 | − | 5 | − | − | |
| 2016 | Bergsland EK ( 5) | 59 | Others: (esophagus,
stomach, small intestine) |
− | 192 | 49 | 29 | 3 | − | 8 | − | 25 | − | − | |
| 2016 | Vijayvergia.N ( 6) | 23 (4) | Colon (9), pancreas (4),
small intestine (1), others (9) |
− | 50 | 57 | 9 | 30 | 13 | 22 | − | − | 22 | − | |
| 2017 | Makuuchi R ( 7) | 6 | Stomach | − | 35 | 100 | 17 | 17 | − | 0 | − | − | 17 | − | |
| 2017 | Woischke C ( 8) | 15 (10) | Colorectum | 11 | 50 | 100 | 30 | 90 | 20 | 80 | − | − | 40 | − | |
| 2018 | Takizawa N ( 9) | 25 | Colorectum | 16 | − | 21 | − | 8 | − | 4 | 4 | − | − | − | |
| 2018 | Moritz J ( 10) | 19 | Colorectum (MiNEN) | − | 32 | 53 | 5 | 21 | 37 | 16 | 0 | − | − | 5 | |
| 2018 | Moritz J ( 10) | 8 | Colorectum (NEC) | 7 | 32 | 63 | 0 | 25 | 25 | 63 | 0 | − | − | 0 | |
| 2018 | Konukiewitz B ( 11) | 12 | Pancreas | 9 | 409 | 67 | 33 | 42 | 8 | 8 | 0 | 8 | 8 | 8 | |
| 2019 | Shamir ER ( 12 | 25 (−) | Colorectum | − | 479 | 38 | 58 | 63 | − | 63 | − | − | − | − | |
| 2019 | Chen LH ( 13) | 83 | Colorectum | − | − | 66 | 17 | 37 | 20 | 60 | − | − | − | − | |
| 2019 | Dizdar L ( 14) | 15 | GEPNEC | − | − | − | − | − | 47 | − | − | − | − | − | |
| 2020 | Krishnamurthy K ( 15) | 2 | GEPNEC | − | 126 | 56 | 0 | − | − | − | 44 | − | − | − | |
| 2020 | Tanaka H ( 16) | 44 | Pancreas | 17 | − | − | 55 | 49 | − | − | − | − | − | − | |
| 2020 | Busico A ( 17) | 39 § | GEP | − | 50 | 59 | − | 3 | 10 | 8 | 5 | − | − | − | |
| 2020 | Puccini A ( 18) | 135 § | GEP | − | 592 | 51 | 11 | 29 | 5 | 27 | − | − | 7 | − | |
| 2021 | Koh J ( 19) | 13 | Stomach (MiNEN) | 12 | 170 | 69 | 0 | 0 | 8 | 31 | 8 | − | − | − | |
| 2021 | Koh J ( 19) | 8 | Stomach (NEC) | 6 | 170 | 88 | 13 | 0 | 0 | 0 | 13 | − | − | − | |
| 2021 | Ishida S (MiNEN) ( 20) | 6 | Stomach | 6 | WES | 67 | 0 | 0 | − | 33 | 17 | − | − | − | |
| 2021 | Ishida S (NEC) ( 20) | 7 | Stomach | 4 | WES | 62 | 14 | 14 | − | 14 | 0 | − | − | − | |
| 2021 | Liu F ( 21) | 15 | Gallbladder | 10 | WES | 73 | 27 | − | 0 | 0 | 27 | − | − | 0 | |
| 2021 | deBitter T ( 22) | 9 (6) | Gallbladder | 5 | 523 | 77 | 33 | 11 | − | 11 | 33 | 0 | 0 | 0 | |
| 2022 | Venizelos A ( 23) ‖ | 181 | GEP/Unknown | − | 360 | 64 | 14 | 22 | 20 | 28 | 6 | 3 | − | − | |
| 2021 | Lee SM ( 24) | 30 | Colorectum | 18 | 382 | 43 | 47 | 53 | 23 | 37 | 0 | 3 | 10 | 7 | |
| 2022 | Yachida ( 25) | 54 | GEP | − | − | 26 | − | − | − | − | − | − | |||
| 2022 | Wu ( 26) | 143 | GEP | WES | 89 | 25 | 8 | − | 18 | − | − | − | − | ||